Zomedica Corp. (NYSEAMERICAN:ZOM) shares gapped down prior to trading on Tuesday following insider selling activity. The stock had previously closed at $1.12, but opened at $1.03. Zomedica shares last traded at $1.08, with a volume of 317,872 shares changing hands.
Specifically, Director Johnny D. Powers sold 750,000 shares of the firm’s stock in a transaction that occurred on Monday, April 12th. The shares were sold at an average price of $1.16, for a total value of $870,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Stephanie Morley sold 805,000 shares of the firm’s stock in a transaction that occurred on Monday, April 12th. The stock was sold at an average price of $1.16, for a total transaction of $933,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 1,764,580 shares of the company’s stock, valued at $2,046,912.80. The disclosure for this sale can be found here. Insiders have sold a total of 1,619,732 shares of company stock valued at $1,878,505 over the last three months.
Separately, Zacks Investment Research raised shares of Zomedica from a “sell” rating to a “hold” rating in a report on Thursday, January 28th.
Zomedica (NYSEAMERICAN:ZOM) last announced its earnings results on Friday, February 26th. The company reported ($0.01) earnings per share (EPS) for the quarter.
A hedge fund recently bought a new stake in Zomedica stock. JPMorgan Chase & Co. acquired a new position in Zomedica Corp. (NYSEAMERICAN:ZOM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 285,800 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned approximately 0.05% of Zomedica at the end of the most recent quarter.
About Zomedica (NYSEAMERICAN:ZOM)
Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies.
Further Reading: What is the Shanghai Stock Exchange Composite Index?
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.